Belgium to Become First EU Country to Ban Disposable E-Cigarettes

Jan.02.2025
Belgium to Become First EU Country to Ban Disposable E-Cigarettes
Belgium to become first EU country to ban disposable e-cigarettes in 2025, while Estonia yet to set national ban.

According to ERR on December 31st, Belgium will become the first EU member state to ban the sale of disposable e-cigarettes starting on January 1, 2025. Meanwhile, in Estonia, a nationwide ban on the sale of disposable e-cigarettes has not yet been scheduled at the national level.


The head of the Department of Environmental Protection and Chemical Safety in the Ministry of Social Affairs, Iive Telling, pointed out that Estonia has been discussing the possibility of banning the sale of disposable e-cigarettes for many years.


The current situation is that we have not implemented a direct ban on e-cigarettes. We support a regulatory approach across Europe at the government level. Implementing bans separately in different countries is much more difficult than establishing a unified regulatory system within the European Union.


She explained that the idea of banning the sale of disposable e-cigarettes throughout the European Union is still in the early stages of discussion. They are studying the positions of each member state and considering different approaches to solving this issue, as the scale of the problem varies from country to country and the products used also differ. Terin believes that implementing a ban in just one country is unlikely to achieve the desired effect, and regulation should be conducted across the entire European Union.


In Estonia, the sale of flavored e-cigarette liquid, apart from tobacco and mint flavors, has been banned. Additionally, cross-border and domestic remote sales of tobacco products, including e-cigarettes, are also prohibited.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
SICPA Secures Five-Year UK Vape Tax Stamp Contract
SICPA Secures Five-Year UK Vape Tax Stamp Contract
HM Revenue and Customs (HMRC) has awarded a five-year contract to Swiss technology company SICPA and Cartor Security Printers to implement the United Kingdom’s new vaping duty stamp and track-and-trace system, beginning in April 2026.
Market
Feb.24
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
Smoore, Distributors Move to Toss Cannabis Vape Price-Fixing Suit
Smoore, Distributors Move to Toss Cannabis Vape Price-Fixing Suit
Several vape manufacturers and distributors, including Shenzhen Smoore Technology Co. Ltd., Smoore International Holdings, 3Win Corp., Jupiter Research LLC, Canna Brand Solutions, and Greenlane Holdings Inc., have filed motions seeking dismissal of consumer claims in consolidated antitrust litigation in the U.S. District Court for the Northern District of California.
Events
Feb.24
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.
Mar.10
BAT Malaysia Launches Workforce Exercise to Improve Efficiency and Align With Future Business Direction
BAT Malaysia Launches Workforce Exercise to Improve Efficiency and Align With Future Business Direction
British American Tobacco Malaysia has announced a workforce optimisation exercise aimed at streamlining operations ahead of a major shift in its distribution strategy.
Apr.01 by 2FIRSTS.ai